MLTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MLTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MoonLake Immunotherapeutics's Enterprise Value is $2,029.44 Mil. MoonLake Immunotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-48.91 Mil. Therefore, MoonLake Immunotherapeutics's EV-to-FCF for today is -41.49.
The historical rank and industry rank for MoonLake Immunotherapeutics's EV-to-FCF or its related term are showing as below:
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-12), MoonLake Immunotherapeutics's stock price is $40.92. MoonLake Immunotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.730. Therefore, MoonLake Immunotherapeutics's PE Ratio for today is At Loss.
The historical data trend for MoonLake Immunotherapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MoonLake Immunotherapeutics Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
EV-to-FCF | - | -6.39 | -73.43 |
MoonLake Immunotherapeutics Quarterly Data | ||||||||||||
Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-FCF | Get a 7-Day Free Trial | -15.61 | -53.06 | -62.38 | -73.43 | -53.66 |
For the Biotechnology subindustry, MoonLake Immunotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where MoonLake Immunotherapeutics's EV-to-FCF falls into.
MoonLake Immunotherapeutics's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 2029.437 | / | -48.914 | |
= | -41.49 |
MoonLake Immunotherapeutics's current Enterprise Value is $2,029.44 Mil.
MoonLake Immunotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MoonLake Immunotherapeutics (NAS:MLTX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
MoonLake Immunotherapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 40.92 | / | -0.730 | |
= | At Loss |
MoonLake Immunotherapeutics's share price for today is $40.92.
MoonLake Immunotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.730.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of MoonLake Immunotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Matthias Bodenstedt | officer: Chief Financial Officer | DORFSTRASSE 29, ZUG V8 6300 |
Bihua Chen | 10 percent owner | C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Private Healthcare Fund Iv Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Global Healthcare Master Fund, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Private Healthcare Fund Iii Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Private Healthcare Fund Ii, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Simon Sturge | director | DORFSTRASSE 29, ZUG V8 6300 |
Kristian Reich | officer: Chief Scientific Officer | DORFSTRASSE 29, ZUG V8 6300 |
Santos Da Silva Jorge | director, officer: Chief Executive Officer | DORFSTRASSE 29, ZUG V8 6300 |
Bvf Partners L P/il | director, 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Andrew John Phillips | director | C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116 |
Ramnik Xavier | director | DORFSTRASSE 29, ZUG V8 6300 |
Spike Loy | director | DORFSTRASSE 29, ZUG V8 6300 |
Kara Lassen | director | DORFSTRASSE 29, ZUG V8 6300 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-01-2022
By PurpleRose PurpleRose • 07-11-2022
By Marketwired • 06-25-2023
By sperokesalga sperokesalga • 05-03-2023
By GuruFocusNews GuruFocusNews • 05-22-2022
By GuruFocus Research • 12-22-2023
By Marketwired • 08-10-2023
By Marketwired • 06-26-2023
By Marketwired • 10-04-2023
By Marketwired • 09-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.